非那雄胺联合盐酸坦洛新治疗良性前列腺增生的短期临床效果
|
摘要
目的探讨非那雄胺联合盐酸坦洛新治疗良性前列腺增生的短期临床效果。方法选择2015年9月至2017年9月82例良性前列腺增生患者为研究对象,按照用药方案分为对照组和研究组,每组41例。对照组给予非那雄胺治疗,研究组给予非那雄胺联合盐酸坦洛新治疗。评价两组的临床疗效,治疗前后国际前列腺症状量表(IPSS)评分、泌尿症状困扰(BS)评分、勃起功能国际问卷(IIEF-5)评分、超声测量指标以及不良反应。结果治疗后研究组的治疗有效率(92.68%)高于对照组(75.61%)(χ~2=4.479,P=0.034)。治疗前两组IPSS评分、BS评分、IIEF-5评分、前列腺体积(PV)、残余尿量(RU)、最大尿流率(Qmax)比较,差异未见统计学意义(P>0.05)。治疗后两组IPSS评分、BS评分、PV、RU均较治疗前降低(P<0.05),且研究组低于对照组(P<0.05);两组的IIEF-5评分、Qmax均较治疗前升高(P<0.05),且研究组高于对照组(P<0.05)。两组不良反应发生率比较,差异未见统计学(χ~2=1.406,P=0.236)。结论非那雄胺联合盐酸坦洛新治疗良性前列腺增生可显著改善患者的症状及超声表现,具有良好的临床疗效,具有积极的临床治疗应用价值。
Objective To investigate the short-term clinical effect of finasteride combined with tamsulosin hydrochloride on benign prostatic hyperplasia.Methods From September 2015 to September 2017, 82 patients with benign prostatic hyperplasia(BPH) were selected as the subjects. According to the drug regimen, the patients were divided into two groups, with 41 cases in each group.The control group was treated with finasteride.The study group was treated with finasteride combined with tamsulosin hydrochloride.The clinical efficacy, IPSS score, BS score, IIEF-5 score, ultrasound measurement index and adverse reactions were evaluated before and after treatment.Results After treatment, the effective rate of the study group(92.68%) was higher than that of the control group(75.61%)(χ~2 = 4.479, P=0.034).There were no significant differences in IPSS score, BS score, IIEF-5 score, prostate volume(PV), residual urine volume(RU), maximum urinary flow rate(Qmax) between the two groups before treatment(P>0.05).After treatment, IPSS score, BS score, PV and RU in both groups were lower than those before treatment(P< 0.05).And those indexes of the research group were lower than those of the control group(P< 0.05).The IIEF-5 score and Qmax in both groups were higher than those before treatment(P< 0.05), and those in the study group were higher than those in the control group(P< 0.05).There was no significant difference in the incidence of adverse reactions between the two groups(χ~2 = 1.406, P= 0.236).Conclusions Finasteride combined with tamsulosin hydrochloride in the treatment of benign prostatic hyperplasia can significantly improve the symptoms and ultrasound manifestations of patients.It has good clinical efficacy and positive clinical application value.
Objective To investigate the short-term clinical effect of finasteride combined with tamsulosin hydrochloride on benign prostatic hyperplasia.Methods From September 2015 to September 2017, 82 patients with benign prostatic hyperplasia(BPH) were selected as the subjects. According to the drug regimen, the patients were divided into two groups, with 41 cases in each group.The control group was treated with finasteride.The study group was treated with finasteride combined with tamsulosin hydrochloride.The clinical efficacy, IPSS score, BS score, IIEF-5 score, ultrasound measurement index and adverse reactions were evaluated before and after treatment.Results After treatment, the effective rate of the study group(92.68%) was higher than that of the control group(75.61%)(χ~2 = 4.479, P=0.034).There were no significant differences in IPSS score, BS score, IIEF-5 score, prostate volume(PV), residual urine volume(RU), maximum urinary flow rate(Qmax) between the two groups before treatment(P>0.05).After treatment, IPSS score, BS score, PV and RU in both groups were lower than those before treatment(P< 0.05).And those indexes of the research group were lower than those of the control group(P< 0.05).The IIEF-5 score and Qmax in both groups were higher than those before treatment(P< 0.05), and those in the study group were higher than those in the control group(P< 0.05).There was no significant difference in the incidence of adverse reactions between the two groups(χ~2 = 1.406, P= 0.236).Conclusions Finasteride combined with tamsulosin hydrochloride in the treatment of benign prostatic hyperplasia can significantly improve the symptoms and ultrasound manifestations of patients.It has good clinical efficacy and positive clinical application value.
引文
[1] 孙自学,李鹏超.中医药治疗良性前列腺增生症研究进展[J].中华中医药杂志,2018,33(6):2482-2484.
[2] Wang M,Guo L,Duan F,et al.Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia:a comparative study of medium and large-volume prostates[J].BJU Int,2016,117(1):155-164.DOI:10.1111/bju.13147.
[3] 卢一平,梁嘉宇.良性前列腺增生微创治疗新进展[J].中华男科学杂志,2016,22(5):387-392.DOI:10.13263/j.cnki.nja.2016.05.001.
[4] 白宇,赵卫,罗罡,等.前列腺动脉栓塞术治疗良性前列腺增生[J].中国介入影像与治疗学,2016,13(4):204-207.DOI:10.13929/j.1672-8475.2016.04.004.
[5] 陈丽曼,刘智芬,胡威威,等.替米沙坦联合非那雄胺对非杓型高血压合并前列腺增生患者血压节律性的影响[J].中国药房,2018,29(3):393-397.DOI:10.6039/j.issn.1001-0408.2018.03.25.
[6] 陈琼,方根强,韩丽,等.托特罗定联合坦洛新在高龄男性良性前列腺增生合并膀胱过度活动症患者中疗效研究[J].中华老年医学杂志,2016,35(5):533-536.DOI:10.3760/cma.j.issn.0254-9026.2016.05.019.
[7] 吴阶平.泌尿外科学[M].济南:山东科学技术出版社,2004:1141.
[8] 王春仙,宫香宇,张素英,等.前列欣联合盐酸坦索罗辛和非那雄胺治疗老年良性前列腺增生的疗效观察[J].中国药房,2017,28(8):1108-1111.DOI:10.6039/j.issn.1001-0408.2017.08.28.
[9] 张晓波,陈明泉,陈雄,等.激光汽化术与前列腺电切术治疗良性前列腺增生疗效的Meta分析[J].中国内镜杂志,2017,23(7):16-21.DOI:10.3969/j.issn.1007-1989.2017.07.004.
[10] La Viqnera S,Condorelli RA,Russo GI,et al.Endocrine control of benign prostatic hyperplasia[J].Andrology,2016,4(3):404-411.DOI:10.1111/andr.12186.
[11] 仲晨,文伟,夏术阶.良性前列腺增生症患者药物与微创治疗的经济学和有效性分析[J].中华医学杂志,2016,96(4):289-292.DOI:10.3760/cma.j.issn.0376-2491.2016.04.013.
[12] 夏蕾,王丽霞.非那雄胺治疗经尿道前列腺切除术出血疗效的meta分析[J].临床药物治疗杂志,2016,14(2):17-22.DOI:10.3969/j.issn.1672-3384.2016.02.005.
[13] 曾锋,曾令浩.盐酸坦洛新缓释胶囊治疗输尿管结石的临床疗效分析[J].临床与病理杂志,2016,36(5):656-660.DOI:10.3978/j.issn.2095-6959.2016.05.024.
[14] 陆海,覃江,韦克暖.盐酸坦洛新缓释片联合前列康片治疗Ⅲ型前列腺炎的疗效观察[J].现代药物与临床,2016,31(4):504-507.DOI:10.7501/j.issn.1674-5515.2016.04.023.
[2] Wang M,Guo L,Duan F,et al.Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia:a comparative study of medium and large-volume prostates[J].BJU Int,2016,117(1):155-164.DOI:10.1111/bju.13147.
[3] 卢一平,梁嘉宇.良性前列腺增生微创治疗新进展[J].中华男科学杂志,2016,22(5):387-392.DOI:10.13263/j.cnki.nja.2016.05.001.
[4] 白宇,赵卫,罗罡,等.前列腺动脉栓塞术治疗良性前列腺增生[J].中国介入影像与治疗学,2016,13(4):204-207.DOI:10.13929/j.1672-8475.2016.04.004.
[5] 陈丽曼,刘智芬,胡威威,等.替米沙坦联合非那雄胺对非杓型高血压合并前列腺增生患者血压节律性的影响[J].中国药房,2018,29(3):393-397.DOI:10.6039/j.issn.1001-0408.2018.03.25.
[6] 陈琼,方根强,韩丽,等.托特罗定联合坦洛新在高龄男性良性前列腺增生合并膀胱过度活动症患者中疗效研究[J].中华老年医学杂志,2016,35(5):533-536.DOI:10.3760/cma.j.issn.0254-9026.2016.05.019.
[7] 吴阶平.泌尿外科学[M].济南:山东科学技术出版社,2004:1141.
[8] 王春仙,宫香宇,张素英,等.前列欣联合盐酸坦索罗辛和非那雄胺治疗老年良性前列腺增生的疗效观察[J].中国药房,2017,28(8):1108-1111.DOI:10.6039/j.issn.1001-0408.2017.08.28.
[9] 张晓波,陈明泉,陈雄,等.激光汽化术与前列腺电切术治疗良性前列腺增生疗效的Meta分析[J].中国内镜杂志,2017,23(7):16-21.DOI:10.3969/j.issn.1007-1989.2017.07.004.
[10] La Viqnera S,Condorelli RA,Russo GI,et al.Endocrine control of benign prostatic hyperplasia[J].Andrology,2016,4(3):404-411.DOI:10.1111/andr.12186.
[11] 仲晨,文伟,夏术阶.良性前列腺增生症患者药物与微创治疗的经济学和有效性分析[J].中华医学杂志,2016,96(4):289-292.DOI:10.3760/cma.j.issn.0376-2491.2016.04.013.
[12] 夏蕾,王丽霞.非那雄胺治疗经尿道前列腺切除术出血疗效的meta分析[J].临床药物治疗杂志,2016,14(2):17-22.DOI:10.3969/j.issn.1672-3384.2016.02.005.
[13] 曾锋,曾令浩.盐酸坦洛新缓释胶囊治疗输尿管结石的临床疗效分析[J].临床与病理杂志,2016,36(5):656-660.DOI:10.3978/j.issn.2095-6959.2016.05.024.
[14] 陆海,覃江,韦克暖.盐酸坦洛新缓释片联合前列康片治疗Ⅲ型前列腺炎的疗效观察[J].现代药物与临床,2016,31(4):504-507.DOI:10.7501/j.issn.1674-5515.2016.04.023.